AML in 2016: Where we are now?. Issue 4 (December 2016)

• Record Type: Journal Article
• Authors: Rowe, Jacob M.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 29:Issue 4(2016)
• Page Start: 315
• Page End: 319
• Publication Date: 2016-12
• Subjects: Acute leukemia forum -- Acute lymphoblastic leukemia -- Acute myeloid leukemia -- ALL -- AML -- Blinatumomab -- Genomics -- IDH -- Minimal residual disease -- MRD; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2016.10.001
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: A high relapse rate for patients with acute myeloid leukemia (AML) is still a major barrier to the long-term survival of these patients. Nevertheless, considerable progress has been made both in the biology and therapy of the disease. Specifically, progress has been made in the areas of integrated genomic analysis for prognosis, the widening application of minimal residual disease (MRD) monitoring in clinical practice, the development of new agents, and the increasing use of drugs, such as IDH and FLT3 inhibitors, as a bridge to transplant. Continued progress and inquiry into these and other areas are essential to improve the survival outcome for adult patients with AML.